Skip to main content
Trisha Zeidan, MD, Endocrinology, Dayton, OH

TrishaLZeidanMD

Endocrinology Dayton, OH

Diabetes, Lipid Metabolism

Physician

Dr. Zeidan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Zeidan's full profile

Already have an account?

  • Office

    Wright State Physicians
    5678 Far Hills Ave
    Dayton, OH 45429
    Phone+1 937-245-7200
    Fax+1 866-777-4959

Summary

  • Dr. Trisha Zeidan is an endocrinologist in Dayton, OH and is affiliated with Miami Valley Hospital. She received her medical degree from The Ohio State University College of Medicine and has been in practice 13 years. She specializes in diabetes and lipid metabolism.

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2007 - 2009
  • Ohio State University Hospital
    Ohio State University HospitalResidency, Internal Medicine, 2004 - 2007
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2004

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2004 - 2025
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Publications & Presentations

PubMed

Press Mentions

  • 10 New Ways Medtech Could Keep Diabetes in Check
    10 New Ways Medtech Could Keep Diabetes in CheckNovember 22nd, 2019
  • Valeritas' V-go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 When Intensifying from a Basal Insulin Regimen to Basal-Bolus Delivery
    Valeritas' V-go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 When Intensifying from a Basal Insulin Regimen to Basal-Bolus DeliveryJune 27th, 2019
  • Medtronic's Latest Real-World Device Data, Onduo and Orpyx's Expanding Partnership and More Diabetes News from ADA 2019
    Medtronic's Latest Real-World Device Data, Onduo and Orpyx's Expanding Partnership and More Diabetes News from ADA 2019June 10th, 2019

Professional Memberships